Nano-Strategies Targeting the Integrin αvβ3 Network for Cancer Therapy

Cells

Jens Z. Pedersen¹  Roberto De Luca²  Sandra Incerpi³  Hung-Yun Lin⁴  Jacqueline Whang-Peng⁴  Wong-Jin Chang⁵  Tsai-Mu Cheng⁵  Hsiu-Yi Chu⁵  Zi-Lin Li⁶  Ya-Jung Shih⁶  Kuan Wang⁶ 

[1] Department of Biology, University of Rome Tor Vergata, 00133 Rome, Italy;Department of Neurology, Center for Life Science, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA;Department of Sciences, University “Roma Tre”, 00154 Rome, Italy;Graduate Institute for Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei 11031, Taiwan;Graduate Institute for Translational Medicine, College of Medical Science and Technology, Taipei Medical University, Taipei 11031, Taiwan;Graduate Institute of Nanomedicine and Medical Engineering, College of Medical Engineering, Taipei Medical University, Taipei 11031, Taiwan;

关键词: integrin αvβ3;    drug-delivery system;    nanomaterial;    NDAT;    resveratrol;    RGD;   

DOI  :  10.3390/cells10071684

来源: DOAJ

【 摘 要 】

Integrin αvβ3, a cell surface receptor, participates in signaling transduction pathways in cancer cell proliferation and metastasis. Several ligands bind to integrin αvβ3 to regulate proliferation and metastasis in cancer cells. Crosstalk between the integrin and other signal transduction pathways also plays an important role in modulating cancer proliferation. Carcinoembryonic antigen cell adhesion molecule 6 (CEACAM6) activates the downstream integrin FAK to stimulate biological activities including cancer proliferation and metastasis. Blockage of signals related to integrin αvβ3 was shown to be a promising target for cancer therapies. 3,3′,5,5′-tetraiodothyroacetic acid (tetrac) completely binds to the integrin with the thyroid hormone to suppress cancer proliferation. The (E)-stilbene analog, resveratrol, also binds to integrin αvβ3 to inhibit cancer growth. Recently, nanotechnologies have been used in the biomedical field for detection and therapeutic purposes. In the current review, we show and evaluate the potentiation of the nanomaterial carrier RGD peptide, derivatives of PLGA-tetrac (NDAT), and nanoresveratrol targeting integrin αvβ3 in cancer therapies.

【 授权许可】

Unknown